Table 1.
Patients’ characteristics.
| Age, median (range) years | 57.9 (28–73) |
| Sex | |
| Male | 32 (64%) |
| Female | 18 (36%) |
| Location | |
| Left colon | 31 (62%) |
| Right colon | 7 (14%) |
| Rectum | 7 (14%) |
| NA | 5 (10%) |
| Metastatic sites at diagnosis | |
| 0 | 17 (34%) |
| >0 | 33 (66%) |
| RAS status | |
| KRAS Mutated | 20 (40%) |
| NRAS Mutated | 1 (2%) |
| RAS Wild-type | 29 (58%) |
| PIK3CA status | |
| Mutated | 6 (12%) |
| Wild-type | 44 (88%) |
| Tissue | |
| Primary | 26 (52%) |
| Liver metastasis | 24 (48%) |
| First-line chemotherapy | |
| Irinotecan + 5FU | 14 (28%) |
| Oxaliplatin + 5FU | 16 (32%) |
| Oxaliplatin + 5FU + anti-EGFR | 8 (16%) |
| Irinotecan + 5FU + anti-EGFR | 9 (18%) |
| Other | 3 (6%) |
| Second-line chemotherapy | |
| Irinotecan + 5FU | 22 (44%) |
| Oxaliplatin + 5FU | 5 (10%) |
| Oxaliplatin + 5FU + anti-EGFR | 2 (4%) |
| Irinotecan + 5FU + anti-EGFR | 13 (26%) |
| anti-EGFR alone | 1 (2%) |
| Not given | 7 (14%) |
| Survival, median (95% confidence interval) months | |
| Survival metastatic setting | 44.3 (40–58) |
| Time to progression first-line | 8.3 (7–11) |
| Time to progression second-line | 6.9 (6–9) |